76
|
|
77
|
Pham-Huu C, Estournes C, Heinrich B, Crouzet C, Ledoux MJ. High Temperature Removal of H2S over Iron Oxide Supported on SiC Sorbent. ACTA ACUST UNITED AC 1997. [DOI: 10.1051/jp4:19971277] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
78
|
Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Diergarten K, Rastetter J, Hanauske AR. Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Oncology 1997; 54:89-95. [PMID: 9075777 DOI: 10.1159/000227669] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We have performed a clinical phase I trial of a combination treatment with paclitaxel given as 3-hour infusion and cisplatin to determine the maximum tolerated dose and the dose-limiting toxicity in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Treatment was repeated every 21 days. Doses administered ranged from 135 mg/m2 paclitaxel/75 mg/m2 cisplatin to 250 mg/m2 paclitaxel/100 mg/m2 cisplatin. Twenty-four patients have been entered into this study. The maximum tolerated dose was determined to be 225-250 mg/m2 paclitaxel/100 mg/m2 cisplatin. The dose-limiting toxicity of this regimen was myelosuppression (granulocytopenia). Neurosensory and neuromotor toxicity was moderate. However, analyses of threshold electrotonus studies indicated subclinical neurotoxicity in most patients. One patient receiving 200 mg/m2 paclitaxel/100 mg/m2 cisplatin developed grade 3 motor-neurotoxicity. Orthostatic hypotension was observed in 8 patients receiving doses of 200 mg/m2 paclitaxel/100 mg/m2 cisplatin or higher. Objective responses were observed at paclitaxel 175 mg/m2/ cisplatin 100 mg/m2 (n = 5; complete response in 1 patient), paclitaxel 200 mg/ m2/cisplatin 100 mg/m2 (n = 3; partial response in 3 patients) and at paclitaxel 225 mg/m2/cisplatin 100 mg/m2 (n = 8; partial response in 1 patient). Eleven additional patients had stable disease. We conclude that paclitaxel administered as a 3-hour infusion followed by cisplatin is an active regimen in advanced head and neck cancer and that orthostatic hypotension may be a potentially significant clinical toxicity.
Collapse
|
79
|
von Kries R, Heinrich B, Böhm O, Windfuhr A, Helwig H. Systemische Haemophilus-influenzae-Erkrankungen in Deutschland: 1992-1995. Monatsschr Kinderheilkd 1997. [DOI: 10.1007/s001120050115] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
80
|
McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J. Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. Br J Cancer 1996; 74:1944-8. [PMID: 8980394 PMCID: PMC2074819 DOI: 10.1038/bjc.1996.657] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. Phase I evaluation found a maximum tolerated rhizoxin dose of 2.6 mg m-2, with reversible, but dose-limiting, mucositis, leucopenia and diarrhoea. Clinical trials were then initiated by the EORTC ECSG in melanoma, breast, head and neck, and non-small-cell lung cancers with the recommended phase II rhizoxin dose of 2 mg m-2. Pharmacological studies were instituted with the phase II trials to complement the limited pharmacokinetic data available from the phase I trial. Blood samples were obtained from 69 of 103 eligible patients enrolled in phase II rhizoxin studies, and these were evaluable for pharmacokinetic analysis in 36 patients. Plasma rhizoxin concentrations were determined by high-performance liquid chromatography (HPLC), and post-distribution pharmacokinetic parameters were estimated by a one-compartment model. Rhizoxin was rapidly eliminated from plasma, with a median systemic clearance of 8.41 min-1 m-2 and an elimination half-life of 10.4 min. Rhizoxin area under the concentration-time curve (AUC) was higher in patients obtaining a partial response or stable disease than in those with progressive disease (median 314 vs 222 ng ml-1 min; P = 0.03). As predicted from previous studies, haematological and gastrointestinal toxicity was observed, but could not be shown to be related to rhizoxin AUC. This study demonstrated the rapid and variable elimination of rhizoxin from the systemic circulation. The presence of pharmacodynamic relationships and the low level of systemic toxicity suggest that future trials of rhizoxin with alternative dosage or treatment schedules are warranted.
Collapse
|
81
|
Kaplan S, Hanauske AR, Pavlidis N, Bruntsch U, te Velde A, Wanders J, Heinrich B, Verweij J. Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer 1996; 73:403-5. [PMID: 8562351 PMCID: PMC2074426 DOI: 10.1038/bjc.1996.70] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was given as an i.v. bolus injection at 2 mg m-2 once every 3 weeks in an outpatient setting. Prophylactic antiemetics were not routinely given. Of the 29 eligible patients, nine had been treated surgically and three had received radiotherapy. The main toxic effects observed were stomatitis (34% of cycles) and neutropenia (41% of cycles). Neutropenic fever was rare (3% of cycles). Twenty-seven patients were evaluable for response. There were four partial responses (15%), while 13 patients (48%) showed stabilisation of their disease. The median duration of response was 7 months (range 6.0-10.7 months) and median survival from the start of rhizoxin treatment was 6 months (range 2-14.7 months). Rhizoxin as single agent shows activity in patients with advanced NSCLC.
Collapse
|
82
|
Venus D, Heinrich B. Interfacial mixing of ultrathin Cr films grown on an Fe whisker. PHYSICAL REVIEW. B, CONDENSED MATTER 1996; 53:R1733-R1736. [PMID: 9983693 DOI: 10.1103/physrevb.53.r1733] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
83
|
Schilling T, Fiebig HH, Kerpel-Fronius S, Winterhalter B, Variol P, Tresca P, Heinrich B, Hanauske AR. Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drugs 1996; 14:371-8. [PMID: 9157072 DOI: 10.1007/bf00180813] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We have performed a high-dose clinical and pharmacokinetic trial with vinorelbine administered as a bolus injection every 21 days. The aim was to evaluate a schedule with longer treatment intervals than one week and to determine the toxicity pattern of such a schedule. A total of 13 patients (pts) with solid tumors (non-small-cell lung [3 pts], unknown primary [3 pts], mesothelioma [2 pts], colon/rectum, sarcoma, thyroid, head/neck and cervix [1 pt each]) were entered [9 male, 4 female, median age: 56 years (range: 37-69)]. Dose levels were 35, 40 and 45 mg/m2 with a total of 26 cycles administered. At 40 mg/m2, 2/6 pts developed grade 4 granulocytopenia. 1/1 pt at 45 mg/m2 developed a grade 4 leuko- and granulocytopenia. Non-hematological toxicities were mild to moderate. Neurologic toxicity except for constipation was mild. Constipation occurred at 35 mg/m2 in 1/6 pts WHO grade 4, at 40 mg/m2 in 2/6 pts WHO grade 3 and at 45 mg/m2 in 1/1 pt WHO grade 4 and was due to neurotoxicity. No objective antitumor response was observed. Vinorelbine pharmacokinetics were analysed in whole blood and plasma and were similar to previously published studies using < or = 30 mg/m2. Our results confirm a high affinity of vinorelbine to corpuscular blood elements. We conclude that the MTD of vinorelbine administered once every 21 days as bolus injection is 40 mg/m2, the dose-limiting toxicities are constipation and granulocytopenia and the recommended dose for subsequent Phase II trials is 35 mg/m2.
Collapse
|
84
|
Hanauske AR, Schilling T, Heinrich B, Kau R, Herzog M, Quasthoff S, Bochtler H, Diergarten K, Rastetter J. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma. Semin Oncol 1995; 22:35-9. [PMID: 8553082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
We performed a clinical phase I trial of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck, using a 3-hour infusion of paclitaxel followed by a 1-hour infusion of cisplatin. Treatment with this combination was repeated every 21 days. Patients who had received prior treatment with platinum-containing regimens were excluded. However, patients who had received two or fewer courses of radiochemotherapy not including platinum compounds were eligible. At present, 21 patients have been entered into this ongoing study. Doses ranged from paclitaxel 135 mg/m2 plus cisplatin 75 mg/m2 to paclitaxel 250 mg/m2 plus cisplatin 100 mg/m2. The maximum tolerated dose was reached at paclitaxel 250 mg/m2 and cisplatin 100 mg/m2. The dose-limiting toxicity of this regimen was myelosuppression (leukopenia, granulocytopenia). Clinically, neurosensory toxicity was moderate. However, preliminary analyses of threshold electrotonus studies indicate the presence of subclinical neurotoxicity in most patients. One patient receiving paclitaxel 200 mg/m2 plus cisplatin 100 mg/m2 developed grade 3 motor neurotoxicity. Profound orthostatic hypotension was observed in five patients receiving paclitaxel 200 mg/m2 plus cisplatin 100 mg/m2 or higher. Neurotoxicity was of delayed onset and slowly reversible, and its severity appeared to be dose related. Twelve patients are currently evaluable for response. Of these, three partial remissions were observed (6, 6+, and 3+ months). Five additional patients had stable disease. We conclude that the combination of paclitaxel administered as a 3-hour infusion followed by cisplatin is an active regimen in advanced head and neck cancer. In addition to myelosuppression, orthostatic hypotension may be a potentially significant clinical toxicity. Clinical phase II studies have been initiated, using a dose of paclitaxel 200 mg/m2 and cisplatin 100 mg/m2.
Collapse
|
85
|
Fullerton EE, Stoeffler D, Ounadjela K, Heinrich B, Celinski Z, Bland JA. Structure and magnetism of epitaxially strained Pd(001) films on Fe(001): Experiment and theory. PHYSICAL REVIEW. B, CONDENSED MATTER 1995; 51:6364-6378. [PMID: 9977176 DOI: 10.1103/physrevb.51.6364] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
86
|
Schurer PJ, Celinski Z, Heinrich B. Mössbauer investigation of the growth of the Fe multilayer in Fe(100)/Ag(100) structures. PHYSICAL REVIEW. B, CONDENSED MATTER 1995; 51:2506-2514. [PMID: 9979007 DOI: 10.1103/physrevb.51.2506] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
87
|
Bland JA, Daboo C, Heinrich B, Celinski Z, Bateson RD. Enhanced magnetic moments in bcc Fe films. PHYSICAL REVIEW. B, CONDENSED MATTER 1995; 51:258-272. [PMID: 9977085 DOI: 10.1103/physrevb.51.258] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
88
|
Bruntsch U, Heinrich B, Kaye SB, de Mulder PH, van Oosterom A, Paridaens R, Vermorken JB, Wanders J, Franklin H, Bayssas M. Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A:1064-7. [PMID: 7654430 DOI: 10.1016/0959-8049(94)90457-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Docetaxel (Taxotere), an analogue of paclitaxel, was tested in a phase II study in advanced renal cell carcinoma. Consenting patients with measurable lesions, adequate organ functions and no prior chemotherapy received 100 mg/m2 of docetaxel as a 1-h infusion every 3 weeks. No premedication to avoid hypersensitivity reactions or nausea and emesis was given. 32 eligible patients received 100 treatment cycles. Short-lasting neutropenia was the dose-limiting toxicity. Acute hypersensitivity reactions (HSR), oedema and skin changes were other important side-effects. HSRs regressed spontaneously or were treated with antihistamines with or without corticosteroids. One partial remission was documented. At the dose and schedule used, docetaxel has only low activity against renal cell carcinoma.
Collapse
|
89
|
Schmid AK, Atlan D, Itoh H, Heinrich B, Ichinokawa T, Kirschner J. Fast interdiffusion in thin films: Scanning-tunneling-microscopy determination of surface diffusion through microscopic pinholes. PHYSICAL REVIEW. B, CONDENSED MATTER 1993; 48:2855-2858. [PMID: 10008699 DOI: 10.1103/physrevb.48.2855] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
90
|
Schurer PJ, Celinski Z, Heinrich B. Mössbauer-effect investigation of the Fe(001)/Ag(001) interface. PHYSICAL REVIEW. B, CONDENSED MATTER 1993; 48:2577-2582. [PMID: 10008652 DOI: 10.1103/physrevb.48.2577] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
91
|
|
92
|
Kowalewski M, Schneider CM, Heinrich B. Thickness and temperature dependence of magnetic anisotropies in ultrathin fcc Co(001) structures. PHYSICAL REVIEW. B, CONDENSED MATTER 1993; 47:8748-8753. [PMID: 10004919 DOI: 10.1103/physrevb.47.8748] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
93
|
Heinrich B, Celinski Z, Cochran JF, Arrott AS, Myrtle K, Purcell ST. Bilinear and biquadratic exchange coupling in bcc Fe/Cu/Fe trilayers: Ferromagnetic-resonance and surface magneto-optical Kerr-effect studies. PHYSICAL REVIEW. B, CONDENSED MATTER 1993; 47:5077-5089. [PMID: 10006672 DOI: 10.1103/physrevb.47.5077] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
94
|
Heinrich B, Celinski Z, Cochran JF, From M. Bilinear and Biquadratic Exchange Coupling in BCC Fe/Cu/Fe Trilayers. Exchange Coupling in Fe Whisker/Cr/Fe(001) Structures. ACTA ACUST UNITED AC 1993. [DOI: 10.1007/978-1-4899-1519-1_16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
|
95
|
Heinrich B. Adaptive Abilities. Science 1993. [DOI: 10.1126/science.705-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
96
|
Gemende B, Heinrich B, Selassie GG, Knaack D, Witzleb W. [RoTrac capillary pore membranes for laboratory filtration. II. Bacteria-free filtration]. ZENTRALBLATT FUR HYGIENE UND UMWELTMEDIZIN = INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL MEDICINE 1992; 193:253-61. [PMID: 1457036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Because of their special characteristics Capillary pore membranes (CPM) are now applied in several branches of separation techniques and analytics. Besides applications in particle analytics and microfiltration of different media capillary pore membranes can be used in microorganism separation. It was shown that RoTrac CPM can be used for bacteria free (or so called sterile) filtration. Acceptable fluxes were reached in separation of Pseudomonas diminuta (test species ATCC 19146). Membranes with pore diameters of 0.2 micron and smaller always assure a bacteria free filtrate even for a very high bacteria count of about 10(7)-10(8) bacteria/ml. In filtration of Mycoplasma arginini no sterile filtrate was obtained for a pore diameter of 0.08 micron and a high bacteria count of 3 * 10(7) bacteria/ml. The bacteria rejection by a factor of 10(5) was however remarkable. Only for 0.05 and 0.08 micron with reduced bacteria load the filtrate was bacteria free.
Collapse
|
97
|
Heinrich B. [Pastoral care of families with children who have cancer]. DEUTSCHE KRANKENPFLEGEZEITSCHRIFT 1992; 45:625-8. [PMID: 1425254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
98
|
Gemende B, Heinrich B, Selassie GG, Knaack D, Witzleb W. [RoTrac capillary pore membranes for laboratory filtration. I. Degermination filtration]. ZENTRALBLATT FUR HYGIENE UND UMWELTMEDIZIN = INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL MEDICINE 1992; 193:188-97. [PMID: 1388619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
RoTrac capillary pore membranes (CPM) are produced by means of the nuclear track technology. Thus a defined and in wide ranges independent adjunction of the different membrane parameters (diameter, density, shape and inclination of pores) is possible. The wanted uniform separation diameter of the membrane can exactly be chosen according to the size of the microorganisms to be rejected. By dead end filtration experiments with E. coli and Serratia marcescens the suitability of RoTrac-CPM in bacteria removal filtration was proven. Blocking was very strong for membranes with pore diameters in size range of the microorganisms (approximately 0.45 micron). Though the filtrate had immense reduced bacteria counts (from 10(7)-10(8) to 10-100 bacteria/ml), it was generally not sterile. For membranes with a pore diameter of 0.2 micron and smaller blocking was essentially lesser. Here filtrate was always sterile. Flux (and thus the filterable volume) corresponds to values of competitive membranes. Compared with those the proven possibility of simple cleaning is an advantage, because rejection and blocking of symmetrical CPM occur directly on the membrane surface. This is promising for use of CPM in cross flow filtration.
Collapse
|
99
|
Cochran JF, Heinrich B. Boundary conditions for exchange-coupled magnetic slabs. PHYSICAL REVIEW. B, CONDENSED MATTER 1992; 45:13096-13099. [PMID: 10001383 DOI: 10.1103/physrevb.45.13096] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
100
|
|